Why the study?
Does halofantrine cause cardiac complications such as QT interval lengthening in treated patients?
Does halofantrine cause cardiac complications such as QT interval lengthening in treated patients?
Halofantrine causes dose-dependent QT interval prolongation, prompting the recommendation for baseline electrocardiography before initiating treatment.
Answers are grounded in this paper and cite their sources.
May support baseline ECG with halofantrine; hypothesis-generating and leaves open need for randomized confirmation.
Halofantrine, increasingly used for treatment of Plasmodium falciparum malaria, is a normally well-tolerated amino-alcohol with very few side-effects, but torsades de pointes ventricular tachycardia due to halofantrine has been reported in a few patients with a congenital long QT interval (Romano-Ward syndrome). We performed a prospective study of the cardiac effect of halofantrine in 20 patients with 48 h ambulatory electrocardiographic (ECG) monitoring; the halofantrine levels in their serum were also determined. Minimal ECG changes were noted, with lengthening of the QT interval without clinical symptoms. This effect was dose-dependent and can be very severe in cases of pre-existing cardiopathy; it also occurs in patients without any pre-existing cardiopathy. In order to reduce the likelihood of such incidents, which are admittedly rare, we suggest performing electrocardiography on all patients before initiating treatment with halofantrine.
No takes yet. Share an insight, caveat, or question.
Monlun et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: